Confirmation of a Metastasis-specific MicroRNA Signature in Primary Colon Cancer

Overview

Journal Sci Rep

Specialty Science

Date 2018 Mar 29

PMID 29588449

Citations 19

Authors

Robert R J Coebergh van den Braak

Anieta M Sieuwerts

Zarina S Lalmahomed

Marcel Smid

Saskia M Wilting

Sandra I Bril

Shanshan Xiang

Michelle van der Vlugt-Daane

Vanja de Weerd

Anne van Galen

Katharina Biermann

J Han J M van Krieken

Wigard P Kloosterman

John A Foekens

John W M Martens

Jan N M IJzermans

Affiliations

Soon will be listed here.

Abstract

The identification of patients with high-risk stage II colon cancer who may benefit from adjuvant therapy may allow the clinical approach to be tailored for these patients based on an understanding of tumour biology. MicroRNAs have been proposed as markers of the prognosis or treatment response in colorectal cancer. Recently, a 2-microRNA signature (let-7i and miR-10b) was proposed to identify colorectal cancer patients at risk of developing distant metastasis. We assessed the prognostic value of this signature and additional candidate microRNAs in an independent, clinically well-defined, prospectively collected cohort of primary colon cancer patients including stage I-II colon cancer without and stage III colon cancer with adjuvant treatment. The 2-microRNA signature specifically predicted hepatic recurrence in the stage I-II group, but not the overall ability to develop distant metastasis. The addition of miR-30b to the 2-microRNA signature allowed the prediction of both distant metastasis and hepatic recurrence in patients with stage I-II colon cancer who did not receive adjuvant chemotherapy. Available gene expression data allowed us to associate miR-30b expression with axon guidance and let-7i expression with cell adhesion, migration, and motility.

Citing Articles

Discovery of Novel miRNAs in Colorectal Cancer: Potential Biological Roles and Clinical Utility.

Minutentag I, Seneda A, Barros-Filhos M, de Carvalho M, Souza V, Hasimoto C Noncoding RNA. 2023; 9(6).

PMID: 37987361 PMC: 10660700. DOI: 10.3390/ncrna9060065.

Dual mechanism of Let-7i in tumor progression.

Zhou J, Xiang H, Cao Z Front Oncol. 2023; 13:1253191.

PMID: 37829341 PMC: 10565035. DOI: 10.3389/fonc.2023.1253191.

An miRNA Signature Predicts Grading of Pancreatic Neuroendocrine Neoplasms.

Saller J, White D, Hough B, Yoder S, Whiting J, Chen D Cancer Genomics Proteomics. 2023; 20(2):154-164.

PMID: 36870693 PMC: 9989673. DOI: 10.21873/cgp.20370.

Overview of microRNAs as liquid biopsy biomarkers for colorectal cancer sub-type profiling and chemoresistance.

Buhagiar A, Seria E, Borg M, Borg J, Ayers D Cancer Drug Resist. 2022; 4(4):934-945.

PMID: 35582382 PMC: 8992439. DOI: 10.20517/cdr.2021.62.

The Future of ctDNA-Defined Minimal Residual Disease: Personalizing Adjuvant Therapy in Colorectal Cancer.

Bent A, Raghavan S, Dasari A, Kopetz S Clin Colorectal Cancer. 2022; 21(2):89-95.

PMID: 35450837 PMC: 9149115. DOI: 10.1016/j.clcc.2022.03.004.

References

Yu F, Deng H, Yao H, Liu Q, Su F, Song E . Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene. 2010; 29(29):4194-204. DOI: 10.1038/onc.2010.167. View

Loher P, Rigoutsos I . Interactive exploration of RNA22 microRNA target predictions. Bioinformatics. 2012; 28(24):3322-3. DOI: 10.1093/bioinformatics/bts615. View

Slattery M, Wolff E, Hoffman M, Pellatt D, Milash B, Wolff R . MicroRNAs and colon and rectal cancer: differential expression by tumor location and subtype. Genes Chromosomes Cancer. 2011; 50(3):196-206. PMC: 3370677. DOI: 10.1002/gcc.20844. View

Yamamoto H, Imai K . Microsatellite instability: an update. Arch Toxicol. 2015; 89(6):899-921. DOI: 10.1007/s00204-015-1474-0. View

Kanehisa M, Goto S . KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 1999; 28(1):27-30. PMC: 102409. DOI: 10.1093/nar/28.1.27. View

Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamauchi M, Nishihara R . Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst. 2013; 105(15):1151-6. PMC: 3735463. DOI: 10.1093/jnci/djt173. View

Wang Y, Li L, Qu Z, Li R, Bi T, Jiang J . The expression of miR-30a* and miR-30e* is associated with a dualistic model for grading ovarian papillary serious carcinoma. Int J Oncol. 2014; 44(6):1904-14. DOI: 10.3892/ijo.2014.2359. View

Pu X, Huang G, Guo H, Guo C, Li H, Ye S . Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol. 2010; 25(10):1674-80. DOI: 10.1111/j.1440-1746.2010.06417.x. View

Robinson M, McCarthy D, Smyth G . edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2009; 26(1):139-40. PMC: 2796818. DOI: 10.1093/bioinformatics/btp616. View

10.

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh J, Comber H . Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013; 49(6):1374-403. DOI: 10.1016/j.ejca.2012.12.027. View

11.

Bitarte N, Bandres E, Boni V, Zarate R, Rodriguez J, Gonzalez-Huarriz M . MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. Stem Cells. 2011; 29(11):1661-71. DOI: 10.1002/stem.741. View

12.

Moreno-Mateos M, Barragan V, Torres B, Rodriguez-Mateo C, Mendez-Vidal C, Berezikov E . Novel small RNA expression libraries uncover hsa-miR-30b and hsa-miR-30c as important factors in anoikis resistance. RNA. 2013; 19(12):1711-25. PMC: 3884670. DOI: 10.1261/rna.039461.113. View

13.

Kobayashi N, Uemura H, Nagahama K, Okudela K, Furuya M, Ino Y . Identification of miR-30d as a novel prognostic maker of prostate cancer. Oncotarget. 2012; 3(11):1455-71. PMC: 3717805. DOI: 10.18632/oncotarget.696. View

14.

Paschos K, Canovas D, Bird N . The role of cell adhesion molecules in the progression of colorectal cancer and the development of liver metastasis. Cell Signal. 2009; 21(5):665-74. DOI: 10.1016/j.cellsig.2009.01.006. View

15.

Lewis B, Burge C, Bartel D . Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120(1):15-20. DOI: 10.1016/j.cell.2004.12.035. View

16.

Gaziel-Sovran A, Segura M, Di Micco R, Collins M, Hanniford D, Vega-Saenz de Miera E . miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell. 2011; 20(1):104-18. PMC: 3681522. DOI: 10.1016/j.ccr.2011.05.027. View

17.

Roth A, Delorenzi M, Tejpar S, Yan P, Klingbiel D, Fiocca R . Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst. 2012; 104(21):1635-46. DOI: 10.1093/jnci/djs427. View

18.

Lin S, Gregory R . MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 2015; 15(6):321-33. PMC: 4859809. DOI: 10.1038/nrc3932. View

19.

Sargent D, Patiyil S, Yothers G, Haller D, Gray R, Benedetti J . End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol. 2007; 25(29):4569-74. DOI: 10.1200/JCO.2006.10.4323. View

20.

Dobin A, Davis C, Schlesinger F, Drenkow J, Zaleski C, Jha S . STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2012; 29(1):15-21. PMC: 3530905. DOI: 10.1093/bioinformatics/bts635. View